Open AccessA PROSPECTIVE RANDOMIZED TRIAL COMPARING INTERLEUKIN-2 RECEPTOR ANTIBODY VERSUS ANTITHYMOCYTE GLOBULIN AS PART OF A QUADRUPLE IMMUNOSUPPRESSIVE INDUCTION THERAPY FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION
Author(s) -
Jan M. Langrehr,
Natascha C. Nüssler,
Ulf Neumann,
Olaf Guckelberger,
R Lohmann,
Arnold Radtke,
Sven Jonas,
J Klupp,
Th. Steinmüller,
H. Lobeck,
Stefan Meuer,
H Schlag,
H. P. Lemmens,
M. Knoop,
H. Keck,
Wolf O. Bechstein,
P. Neuhaus
Publication year - 1997
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199706270-00012
Subject(s) - medicine , gastroenterology , azathioprine , prednisolone , liver transplantation , incidence (geometry) , immunosuppression , randomized controlled trial , regimen , globulin , prospective cohort study , liver function , transplantation , immunology , surgery , physics , disease , optics
Quadruple immunosuppressive induction therapy has been shown to markedly reduce the incidence of acute rejection episodes without increasing the incidence of infectious complications after liver transplantation. However, the use of polyclonal antibody preparations (e.g. antithymocyte globulin [ATG]) is associated with side effects such as fever and tachycardia. To evaluate the efficacy and the safety of a monoclonal antibody directed against the interleukin-2 receptor (BT563) in comparison with ATG as part of a quadruple induction regimen, a prospective, randomized study was conducted.